



<b>Magellan Healthcare</b>	
<b>Clinical guideline</b> <b>PROSTATE CANCER</b>	<b>Original Date:</b> March 2011 <b>Page 1 of 6</b>
<b>Radiation Oncology</b>	<b>Last Review Date:</b> July 2017
<b>Guideline Number:</b> NIA_CG_124	<b>Last Revised Date:</b> July 2017
<b>Responsible Department:</b> <b>Clinical Operations</b>	<b>Implementation Date:</b> January 2018

## INTRODUCTION:

Prostate cancer is diagnosed by biopsy and evaluated (staged) to determine extent of disease (local, regional, or distant metastatic). Both surgery and radiation therapy is used to treat prostate cancers that are organ-confined or extend into tissues adjacent to the prostate. Daily prostate localization can be accomplished with imaging modalities, e.g., ultrasound images, computed tomography (CT) images, or implanted fiducial markers, incorporated into an image guided radiation therapy (IGRT) system.

Patients with very low risk disease should be considered for active surveillance if their life expectancy is less than or equal to 20 years. Active surveillance is as well recommended for patients with favorable intermediate-risk prostate cancer. Observation is the preferred action for men with low-risk prostate cancer with a life expectancy of less than 10 years . Patients with intermediate risk disease may be considered for short course (4-6 months) of neoadjuvant/concomitant/adjuvant ADT. Patients with high risk disease may be considered for pelvic lymph node irradiation and 2-3 years of neoadjuvant/adjuvant ADT.

Initial Clinical Reviewers (ICRs) and Physician Clinical Reviewers (PCRs) must be able to apply criteria based on individual needs and based on an assessment of the local delivery system.

## INDICATIONS FOR RADIATION THERAPY AND TREATMENT OPTIONS

**Very Low Recurrence Risk (Primary Tumor Stage [T] is T1c, PSA <10 ng/ml, and Gleason score  $\leq$  6, PSA density <0.15ng/nl per g, < 3biopsy cores positive with  $\leq$  50% cancer in each)**

- Active surveillance (discussed with patient as treatment option)
- External Beam Radiation Therapy
  - Highly conformal radiation therapy technique (3D-CRT/IMRT) – doses 75 – 79.2 Gy (up to 44 fractions) with IGRT
- LDR (low dose-rate) or HDR (high dose-rate) Brachytherapy

**Low Recurrence Risk (Primary Tumor Stage [T] is T1-T2a, PSA <10 ng/ml, and Gleason score  $\leq$  6)**

- Active surveillance (discussed with patient as treatment option)
- External Beam Radiation Therapy
  - Highly conformal radiation therapy technique (3D-CRT/IMRT) – doses 75 – 79.2 Gy (up to 44 fractions) with IGRT

- SBRT delivered at five fractions or less at 6.5 Gy per fraction or greater. Appropriate as a standalone radiation modality and not as a boost to other conventional methods of radiation treatment.
- LDR (low dose-rate) or HDR (high dose-rate) Brachytherapy

**Intermediate Recurrence Risk (Primary Tumor Stage [T] T2b-T2c or PSA 10-20 ng/ml or Gleason score 7)**

- External Beam Radiation Therapy
  - Highly conformal radiation therapy technique (3D-CRT/IMRT) – doses 75 – 81 Gy (up to 45 fractions)
  - SBRT delivered at five fractions or less at 6.5 Gy per fraction or greater. Appropriate as a standalone radiation modality and NOT as a boost to other conventional methods of radiation treatment.
- Brachytherapy (LDR/HDR) boost combined with EBRT after 40 -50 Gy

**High Recurrence Risk (Primary Tumor Stage [T] T3a or PSA >20 ng/ml or Gleason score 8 - 10 , or two or more intermediate risk factors)**

- External Beam Radiation Therapy
  - Highly conformal radiation therapy technique (3D-CRT/IMRT) – doses up to 81 Gy (up to 45 fractions) with IGRT
- Brachytherapy (LDR/HDR) boost combined with EBRT after 40-50 Gy

**Very High Recurrence Risk (Primary Tumor Stage [T] T3b-T4) with Gleason score 8-10 without Metastasis**

- External Beam Radiation Therapy
  - Highly conformal radiation therapy technique (3D-CRT/IMRT) – doses up to 81 Gy (up to 45 fractions) with IGRT
- Brachytherapy (LDR/HDR) boost combined with EBRT after 40-50 Gy

**Radiation Therapy for Patients with Locally Advanced or Metastatic Prostate (T3b – T4, or any T and N1, M0 disease)**

- External Beam Radiation Therapy
  - Highly conformal radiation therapy technique (3D-CRT/IMRT) – Doses up to 81 Gy (up to 45 fractions) with IGRT

**Post-Prostatectomy**

- One of the following must be met:
  - Detectable PSA or initially undetectable PSA, but with recent detectable and rising values on 2 or more measurements with no evidence of metastatic disease
  - Positive margins
  - Seminal vesicle invasion
  - Gleason 8-10
- Pathological T3 disease External Beam Radiation Therapy
  - Highly conformal radiation therapy technique (3D-CRT/IMRT) Doses 64 – 72 Gy (up to 40 fractions) with IGRT

## TREATMENT OPTIONS REQUIRING PHYSICIAN REVIEW:

The radiation treatment options below require review by a physician reviewer and may include deliberation on whether or not active surveillance and surgery have been considered prior to the decision to request radiation therapy:

- Brachytherapy alone (monotherapy) may be approved for Intermediate Recurrence Risk (Primary Tumor Stage [T] T2b-T2c or PSA 10-20 ng/ml or Gleason score 7) upon review with a physician reviewer. Brachytherapy alone is not considered appropriate if the patient has multiple intermediate risk factors and is thus higher risk.
- Proton beam is not an approved treatment option for localized prostate cancer. Studies comparing proton beam therapy alone to 3-D conformal radiation or IMRT are limited. Overall, studies have not shown clinical outcomes to be superior to conventional radiation therapy.

## REFERENCES

- Abdel-Wahab M, Mahmoud O, Merrick G, et al. Expert Panel on Radiation Oncology-Prostate. ACR Appropriateness Criteria® External Beam Radiation Therapy Treatment Planning for Clinically Localized Prostate Cancer. [online publication]. Reston (VA): American College of Radiology (ACR); 2011. Available at: <http://guideline.gov/content.aspx?f=rss&id=35164>. Accessed on April 22, 2014.
- American Society of Therapeutic Radiation Oncology (ASTRO). Choosing Wisely Released September 23, 2013 (1-5) and September 15, 2014 (6-10) Retrieved February 24, 2015 from: <http://www.choosingwisely.org/doctor-patient-lists/american-society-for-radiation-oncology/>
- American Society of Therapeutic Radiation Oncology (ASTRO). Stereotactic Body Radiation Therapy (SBRT). Updated 4-17-13. Retrieved February 27, 2015 from: [https://www.astro.org/uploadedFiles/Main\\_Site/Practice\\_Management/Reimbursement/2013HPcoding%20guidelines\\_SBRT\\_Final.pdf](https://www.astro.org/uploadedFiles/Main_Site/Practice_Management/Reimbursement/2013HPcoding%20guidelines_SBRT_Final.pdf)
- American Society of Therapeutic Radiation Oncology (ASTRO). SBRT offers prostate cancer patients high cancer control and low toxicity in fewer treatments. September 26, 2016. Retrieved May 11, 2017 from: <https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2016/SBRT-offers-prostate-cancer-patients-high-cancer-control-and-low-toxicity-in-fewer-treatments/>
- Choosing Wisely. Retrieved on May 11, 2017 from The American Society for Radiation Oncology list found at: [http://www.choosingwisely.org/clinician-lists/#keyword=Prostate&parentSociety=American\\_Society\\_for\\_Radiation\\_Oncology](http://www.choosingwisely.org/clinician-lists/#keyword=Prostate&parentSociety=American_Society_for_Radiation_Oncology)
- Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A. Intensity-modulated radiotherapy for the treatment of prostate cancer: A systematic review and economic evaluation. Health Technol Assess. 2010; 14 (47):1-108, iii-iv.
- Institute of Cancer Research, United Kingdom. Intensity-Modulated Radiation Therapy in Treating Patients with Localized Prostate Cancer. NCT00392535. Last updated May 19, 2011. Available at: <http://clinicaltrials.gov/ct2/show/NCT00392535?term=imrt&recr=Open&type=Intr&phase=12&rank=28>
- Clark EE, Thielke A, Kriz H, et al. Intensity modulated radiation therapy. Final Evidence Report. Prepared by the Oregon Health & Science University, Center for Evidence-based Policy for the Washington State Health Care Authority, Health Technology Assessment Program. Olympia, WA: Washington State Health Care Authority, Health Technology Assessment Program; August 20, 2012. Available at: [http://www.hca.wa.gov/hta/Pages/intensity\\_radiation.aspx](http://www.hca.wa.gov/hta/Pages/intensity_radiation.aspx).
- Freeman DE, et al: Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011 Jan 10;6:3.

- Kang JK et al: Image-guided stereotactic body radiation therapy for localized prostate cancer. *Tumori*. 2011 Jan-Feb;97(1):43-8.
- Katz AJ. CyberKnife® Radiosurgery for Prostate Cancer. *Technol Cancer Res Treat*. 2010 Oct; 9(5):463-472. Accessed November 14,2014.  
<http://www.tcr.org/c4304/c4309/CyberKnife-Radiosurgery-for-Prostate-Cancer-463-472-p17811.html>
- Katz AJ, Santoro M. Quality of life and efficacy for stereotactic body radiotherapy for treatment of organ confined prostate cancer. *Int J Radiat Oncol Biol Phys*. 2010 Nov 1; 78(3):S58. Abstract 123. Accessed November 14, 2014.  
[http://www.redjournal.org/article/S0360-3016\(10\)01143-0/fulltext](http://www.redjournal.org/article/S0360-3016(10)01143-0/fulltext)
- King C. Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial. *Front Radiat Ther Oncol*. 2011;43:428-37. Epub 2011 May 20.
- King CR et al: Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. *Int J Radiat Oncol Biol Phys*. 2012 Feb 1;82(2):877-82. Epub 2011 Feb 6.
- Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2010; 76(2):361-368.  
[http://www.astro.org/uploadedFiles/Main\\_Site/Practice\\_Management/Reimbursement/A-STRO%20PBT%20Model%20Policy%20FINAL.pdf](http://www.astro.org/uploadedFiles/Main_Site/Practice_Management/Reimbursement/A-STRO%20PBT%20Model%20Policy%20FINAL.pdf)  
[https://www.astro.org/uploadedFiles/Main\\_Site/Practice\\_Management/Reimbursement/2013HPcoding%20guidelines\\_SBR\\_T\\_Final.pdf](https://www.astro.org/uploadedFiles/Main_Site/Practice_Management/Reimbursement/2013HPcoding%20guidelines_SBR_T_Final.pdf)
- Muacevic A, et al: Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. *Urol Oncol*. 2011 Apr 8.
- National Comprehensive Cancer Network (NCCN). Prostate Cancer Version 2.2017 Retrieved May 11, 2017 from:  
[https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf)
- Oermann EK, et al: Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. *J Hematol Oncol*. 2011 Mar 27;4:12.
- Thompson IM<sup>1</sup>, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS Jr, Faraday MM. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. *J Urol*. 2013 Aug; Accessed May 20, 2016 at: <http://www.ncbi.nlm.nih.gov/pubmed/23707439>
- Yu JB, et al: Proton versus Intensity-Modulated Radiotherapy for Prostate Cancer Patterns of Care and Early Toxicity, *J Natl Cancer Inst*. 2013;105(1):25-32.

Reviewed/Approved by *Michael Pentecost MD* Michael Pentecost, MD, Chief Medical Officer